Home › Trials › NCT03620786
Clinical trial Recruiting at 1 site Observational Ages 40 to 85 Men only

Using HIFU to treat prostate cancer

Official title: High-Intensity Focused Ultrasound for Focal Ablation of Prostate Tissue: An Observational Study of Multiparametric MRI and Ultrasound Fusion Imaging for Guidance

Run by University of California, Los Angeles · NCT03620786 · Data updated 2026-11-12

This study looks at how well High Intensity Focused Ultrasound (HIFU) works for treating prostate cancer and how it affects patients' quality of life before and after the treatment.

Quick facts

Study typeObservational
Ages40 Years to 85 Years
SexMen only
Enrollment100 (estimated)
SponsorUniversity of California, Los Angeles
Academic / other
Drugs / interventionsradiation
Locations1 site (Los Angeles, California)
StatusRecruiting
StartedSeptember 26, 2018
Main results expectedJanuary 31, 2027
Study endsJanuary 31, 2028
Registry record updatedApril 16, 2026
Trial IDNCT03620786 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are men aged 40 to 85 who have elected to receive HIFU therapy for prostate cancer and have declined other treatment options.

Probably not a fit

Patients who have previously undergone treatment for prostate cancer or have medical contraindications to follow-up procedures may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the effectiveness of High Intensity Focused Ultrasound (HIFU) for the localized treatment of prostate cancer. Participants will have already chosen or undergone HIFU therapy as part of their standard care. The study will collect clinical data and health-related quality of life (HRQOL) information through medical record reviews and questionnaires before and after the HIFU procedure. The goal is to assess the outcomes and experiences of patients receiving this treatment.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the effectiveness and quality of life outcomes associated with HIFU treatment for prostate cancer.

How similar studies have gone: Other studies have shown promise with HIFU for prostate cancer, indicating that this approach has potential based on previous findings.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Age 40 years to 85 years
2. Subject has elected or already undergone HIFU therapy as their standard of care treatment methodand declined alternative treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone therapy)
3. PSA ≤ 20
4. Prostate volume of ≤ 70 cc
5. Ability to complete informed consent form

Exclusion Criteria:

1. Prior treatment for prostate cancer (with the exception of androgen deprivation therapy)
2. Medical contraindication to follow-up mpMRI or prostate biopsy
3. Unable to tolerate general or regional anesthesia
4. Positive bone scan (only if bone scan has been done or clinically indicated. Bone scan does not need to be performed for study eligibility determination.)

Where it's running

  • University of California, Los Angeles
    Los Angeles, California, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464University of California Los Angeles 1874
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.